ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
45 hedge funds and large institutions have $84.1M invested in ESSA Pharma in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 17 reducing their positions, and 17 closing their positions.
35% more capital invested
Capital invested by funds: $62.2M → $84.1M (+$21.9M)
0.97% less ownership
Funds ownership: 76.68% → 75.72% (-0.97%)
17% less funds holding
Funds holding: 54 → 45 (-9)
47% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 17
50% less call options, than puts
Call options by funds: $109K | Put options by funds: $216K
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$6.79M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$5.74M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.53M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$2.33M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$759K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.84M |
| 2 |
RI
RTW Investments
New York
|
-$2.39M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.74M |
| 4 |
O
OrbiMed
New York
|
-$790K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$760K |
EPIX Hedge Fund Activity: Q4 2022 in Review
45 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2022, worth a combined $84.1M — up 35% from $62.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EPIX and 8 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 9 added.
The largest buyer was PFM Health Sciences, adding an estimated $6.79M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.84M sold.
- 45 institutional investors held ESSA Pharma (EPIX) as of Q4 2022, down from 54 in Q3 2022.
- Funds reported $84.1M of ESSA Pharma stock for Q4 2022, up 35% quarter-over-quarter.
- 8 funds opened new ESSA Pharma positions in Q4 2022 and 17 closed out, a net change of -9 holders.
- The largest ESSA Pharma buyer in Q4 2022 was PFM Health Sciences, an estimated $6.79M added.
- The largest ESSA Pharma seller in Q4 2022 was Eventide Asset Management, an estimated $2.84M sold.
Based on aggregated 13F filings for Q4 2022.